Sumanta Kumar Pal, MD
A handful of immunotherapy and targeted therapy advancements in the field of renal cell carcinoma (RCC) were presented during the 2017 ESMO Congress, highlighting the tremendous growth in this field.
Sumanta Kumar Pal, MD, associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
OncLive: Could you compare the findings of the CheckMate-214 and CABOSUN trials in RCC?
This is a very interesting time in metastatic renal cell carcinoma. At this meeting, specifically, we have 2 very critical data sets. One pertains to the regimen of nivolumab/ipilimumab, which is being evaluated in CheckMate-214—a randomized trial comparing that regimen against sunitinib. This study appears to have an OS benefit and a benefit in terms of response rate. There is no significant difference in PFS, but it is still pretty compelling. What we do know is that it looks like there might be a selected benefit in those patients who are PD-L1 positive. That is something worth highlighting.
... to read the full story